Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) Overview 7 Therapeutics Development 8 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Stage of Development 8 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Therapy Area 9 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Indication 10 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Companies 13 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development 19 Actelion Ltd 19 Eisai Co., Ltd. 20 Evotec AG 21 Heptares Therapeutics Limited 22 Johnson & Johnson 23 Merck & Co., Inc. 24 Novartis AG 25 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles 26 DORA-12 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 HTL-6641 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 JNJ-42847922 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 lemborexant - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 MK-8133 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Dormant Projects 38 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products 39 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Featured News & Press Releases 40 Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 40 Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 41 Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 41 Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 42 Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 42 Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 43 Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 44 Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 45 Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 46 Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 46 Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 47 Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 47 Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 49 May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 50 May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Actelion Ltd, H1 2016 19 Pipeline by Eisai Co., Ltd., H1 2016 20 Pipeline by Evotec AG, H1 2016 21 Pipeline by Heptares Therapeutics Limited, H1 2016 22 Pipeline by Johnson & Johnson, H1 2016 23 Pipeline by Merck & Co., Inc., H1 2016 24 Pipeline by Novartis AG, H1 2016 25 Dormant Projects, H1 2016 38 Discontinued Products, H1 2016 39List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Stage and Routes of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 18

Actelion Ltd Eisai Co., Ltd. Evotec AG Heptares Therapeutics Limited Johnson & Johnson Merck & Co., Inc. Novartis AG